Total Credits: 7
AGENDA - ALL Times Listed PACIFIC
Learning Objectives:
An update on Women and Heart Disease
– Review the traditional and emerging risk factors for CV disease in women
– Discuss the impact of menopause on CV disease
– Review CV disease preventative therapies in women
Behavioral Health Primer for Family Medicine: ACES and Substance Abuste
– Know three examples of the link between trauma, pain and substance use
– Know three effects of trauma on brain development
– Know three ways Substance Use helps one cope with the effects of trauma
– Know three ways to help those with a history of trauma
Making Sense of US Hypertension Guidelines in 2019
At the end of this 50-minute presentation, the awake audience member should be able to:
– Name at least one advantage and at least one disadvantage for the seven (7) sets of US hypertension guideline(s) promulgated since 2002.
– Interpret the results of the Systolic blood PRessure INtervention Trial (SPRINT), its SPRINT-MIND substudy, and summarize their impact on the 2017 ACC/AHA US Hypertension Guideline.
– Explain why, using clinical trial evidence, the recommended initial drug therapy for hypertension varies according to race/ethnicity, in all guidelines since JNC 7
| Metabolic Syndrome and Immune Dysfunction from an Osteopathic Perspective (2.5 MB) | Available after Purchase | ||
| An update on Women and Heart Disease (684.4 KB) | Available after Purchase | ||
| Approach to a Patient with Renal Disease (891.2 KB) | Available after Purchase | ||
| Understanding Glomerular Disease (1.1 MB) | Available after Purchase | ||
| Making Sense of US Hypertension Guidelines in 2019 (2.4 MB) | Available after Purchase | ||
Dr. Carlisle Holland received his medical degree from Texas College of Osteopathic Medicine in 1977 and is board certified in Family Practice with a special proficiency certification in osteopathic manipulation. Dr. Holland chaired a national committee on credentials in osteopathic technique for the American Academy of Osteopathy from 1988 to 1997 and is a member of the Bureau of Experts for the Osteopathic Profession.
He is an internationally recognized authority on the use of osteopathic manipulation in the treatment of children as well as treatment of injuries to the head, nervous system and musculoskeletal system, and has over thirty years of clinical experience treating neurological disorders and complex medical conditions.
Dr. Kathleen Drinan graduated from the University of Michigan College of Pharmacy prior to entering the Chicago College of Osteopathic Medicine where she earned her DO Degree. She completed her Internal Medicine residency and Cardiology fellowship at the Chicago Osteopathic Medical Centers, where she joined the academic practice of cardiology. Dr. Drinan subsequently transitioned to private practice in the Chicago area, where she continues to enjoy her practice of Clinical Cardiology. Dr. Drinan is a Fellow in the American College of Osteopathic Internists and is also a Fellow in the American College of Cardiology. She has completed additional training in Echocardiography and Lipidology and has been recognized as a Diplomat in the National Board of Echocardiography and a Clinical Lipid Specialist in the American Board of Clinical Lipidology.
Dr. Mark Baldwin graduated from Kansas City University of Medicine and Biosciences – College of Osteopathic Medicine in 1983. He completed a rotating internship and residency in Internal Medicine at the Chicago College of Osteopathic Medicine – Midwestern University and a fellowship in Renal Disease and Hypertension at Loyola University Medical Center in Chicago, Illinois. Dr. Baldwin is board certified in Internal Medicine and Nephrology by the American Osteopathic Board of Internal Medicine and as a Medical Examiner by the National Board of Osteopathic Medical Examiners. He is also certified as a Specialist in Clinical Hypertension by the American Society of Hypertension.
During his twenty-plus years in private practice in Columbus, Ohio, Dr. Baldwin was actively involved in all medical education levels. He developed and taught the renal curriculum at the West Virginia School of Osteopathic Medicine for fifteen years. Dr. Baldwin is a Professor and Chair of the Department of Internal Medicine at Pacific Northwest University of Health Sciences, College of Osteopathic Medicine in Yakima, Washington. He is involved in research on chronic kidney disease in agricultural workers and has received numerous teaching awards.
Dr. Baldwin discloses that he has no relevant financial relationships with any organization producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients relative to the content of this presentation.
Jonathan Betlinski, M.D., is a Clinical Associate Professor in the Department of Psychiatry at Oregon Health & Science University, and Director of the Division of Public Psychiatry. Among other projects, he serves as Medical Director for the Oregon Psychiatric Access Line about Adults, as a Lead Faculty for the Oregon ECHO Network, as Program Committee Chair for the Oregon Psychiatric Physicians Association, and as a certified trainer for adult and youth Mental Health First Aid.
William J. Elliott, M.D., Ph.D. is Professor of Preventive Medicine, Internal Medicine, and Pharmacology, Chief of the Division of Pharmacology, and Chair of The Department of Biomedical Sciences at the Pacific Northwest University of Health Sciences in Yakima, WA. After receiving the B.S. (summa cum laude) from the University of Notre Dame, he earned the M.D. and Ph.D. (in Bio-Organic Chemistry) from the University of Chicago. He trained in Internal Medicine and Pharmacology at Barnes Hospital and Washington University—St. Louis, and served as a member of the faculty of the University of Chicago from 1985-92. During the next 17 years at RUSH Medical College, he practiced, taught and did research on cardiovascular clinical pharmacology, focusing on epidemiologic studies of risk factors (including diagonal earlobe creases), laboratory investigations, federally-funded cooperative clinical trials, and many industry-supported endeavors, serving as principal investigator for about 200 clinical trials of new drugs. Dr. Elliott holds Board Certification in both Internal Medicine and Clinical Pharmacology. One of the inaugural “Specialists in Clinical Hypertension” and Fellows of the American Society of Hypertension, he contributed on five topics to JNC VI, as well as to the “long version” of JNC 7. Some of his recent publications include meta-analyses of clinical trial results, putative risk factors for cardiovascular disease, cost-containment, pharmacoeconomics, and the assessment and enhancement of medication adherence. Dr. Elliott belongs to many professional societies interested in clinical pharmacology and in hypertension, including fellowship in the American Heart Association’s High Blood Pressure Council. He has lectured on five continents, participated in the review process for many journals, societies, study sections, and funding agencies, and served as editor or co-editor for many books, monographs, and symposia. Among his honors are 29 awards for teaching excellence.
Dr. William Elliott discloses that he has author and editor relationships with Elsevier and Wolters Kluwer for which he received royalties. He discloses that he has no other relevant financial relationships with any organization producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients relative to the content of his presentation.
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|